These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it. Sun HP, Zhu J, Chen FH, Zhang SL, Zhang Y, You QD. Eur J Med Chem; 2011 Sep 15; 46(9):3942-52. PubMed ID: 21708416 [Abstract] [Full Text] [Related]
16. Disulfide-mediated stabilization of the IκB kinase binding domain of NF-κB essential modulator (NEMO). Zhou L, Yeo AT, Ballarano C, Weber U, Allen KN, Gilmore TD, Whitty A. Biochemistry; 2014 Dec 23; 53(50):7929-44. PubMed ID: 25400026 [Abstract] [Full Text] [Related]
17. Structure and dynamics of the kinase IKK-β--A key regulator of the NF-kappa B transcription factor. Kalia M, Kukol A. J Struct Biol; 2011 Nov 23; 176(2):133-42. PubMed ID: 21820058 [Abstract] [Full Text] [Related]
18. Tautomycetin suppresses the TNFalpha/NF-kappaB pathway via inhibition of IKK activation. Mitsuhashi S, Shima H, Li Y, Tanuma N, Okamoto T, Kikuchi K, Ubukata M. Int J Oncol; 2008 Nov 23; 33(5):1027-35. PubMed ID: 18949366 [Abstract] [Full Text] [Related]
20. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, Habiel DM, Miller F, Jiang HP, Li J, Pardi R, Palumbo R, Olivotto E, Kew RR, Bianchi ME, Marcu KB. J Immunol; 2010 Apr 15; 184(8):4497-509. PubMed ID: 20231695 [Abstract] [Full Text] [Related] Page: [Next] [New Search]